Naveen Krishnan, MD is the Managing Director of Mirae Asset Capital Life Science with nearly 20 years of experience in healthcare spanning biomedical research, clinical/medical training, biotech operating experience, and venture capital investing. Prior to leading Mirae Asset Capital Life Science, he helped lead healthcare investments for Bayer as part of its venture arm, Leaps by Bayer. In this role Dr. Krishnan sat on the board of seven companies and led or supported over 20 deals over the past few years including companies that underwent exit, developed partnerships with big pharma, or became profitable. Prior to Bayer he helped build biotech companies in cell and gene therapy (Aspen Neuroscience) and regenerative medicine including leading operations, business and corporate development, clinical trials, clinical operations, and analytics for public and private companies. Before building biotech companies, Dr. Krishnan was a surgical resident based out of Georgetown University Hospital in Washington, D.C. Dr. Krishnan received his Bachelor’s degree in Brain and Cognitive Sciences from MIT, a Master’s degree in Public Health from the University of Cambridge (Gates Cambridge Scholar), and his medical degree from Dartmouth (Albert Schweitzer Fellow, Dartmouth International Health Group Fellow).